RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SK Biopharmaceuticals Co - Stock

SK Biopharmaceuticals Co ROA 2024

SK Biopharmaceuticals Co ROA

-0.05

Ticker

326030.KS

ISIN

KR7326030004

In 2024, SK Biopharmaceuticals Co's return on assets (ROA) was -0.05, a -78.34% increase from the -0.21 ROA in the previous year.

SK Biopharmaceuticals Co Aktienanalyse

What does SK Biopharmaceuticals Co do?

SK Biopharmaceuticals Co Ltd is a leading bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in South Korea and has been listed on the Korean Stock Exchange since 2014. The history of SK Biopharmaceuticals dates back to 1998 when it was established as a joint venture between SK Group and Hanmi Pharmaceutical. SK Biopharmaceuticals works closely with its parent companies, utilizing their extensive experience and infrastructure in research and development, production, and marketing. The business model of SK Biopharmaceuticals is based on creating value through research and development of drugs for the global market. Within this framework, the company develops innovative bio-pharmaceutical solutions for a range of therapeutic areas, particularly CNS disorders. SK Biopharmaceuticals strives to establish a strong presence in the global bio-pharmaceutical market through partnerships and strategic alliances with other companies. SK Biopharmaceuticals is organized into various divisions, including research and development, production, sales, and marketing. Each of these divisions is tailored to meet the needs of customers and patients to ensure optimal access to medications. The company has various products with different indications on the market worldwide, including the anticonvulsant Brivaracetam, which is approved for the treatment of epilepsy. Brivaracetam is a fast-acting, highly selective, and potent anticonvulsant that demonstrates significant reduction in seizure frequency in patients with epilepsy. SK Biopharmaceuticals continuously works to expand its product portfolio and develop innovative solutions for the treatment of neurological disorders. In addition to drug development for the global market, SK Biopharmaceuticals is also active in the field of biotechnology. The company is committed to harnessing the latest advancements in biotechnology and genomics to support the discovery, development, and commercialization of medications. SK Biopharmaceuticals has established itself as a leading company in the bio-pharmaceutical industry. The company is dedicated to excellence in research, development, and marketing of innovative solutions for the treatment of neurological disorders. With a strong global presence and a dedicated workforce, SK Biopharmaceuticals is well-positioned to further expand its position as a pioneer in the bio-pharmaceutical industry. SK Biopharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding SK Biopharmaceuticals Co's Return on Assets (ROA)

SK Biopharmaceuticals Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing SK Biopharmaceuticals Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider SK Biopharmaceuticals Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in SK Biopharmaceuticals Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about SK Biopharmaceuticals Co Stock

What is the Return on Assets (ROA) of SK Biopharmaceuticals Co this year?

The Return on Assets (ROA) of SK Biopharmaceuticals Co is -0.05 undefined this year.

What was the ROA of SK Biopharmaceuticals Co compared to the previous year?

The ROA of SK Biopharmaceuticals Co has increased by -78.34% compared to the previous year.

What consequences do high ROA have for investors of SK Biopharmaceuticals Co?

A high ROA is advantageous for investors of SK Biopharmaceuticals Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in SK Biopharmaceuticals Co?

A low ROA can be unfavorable for investors of SK Biopharmaceuticals Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of SK Biopharmaceuticals Co affect the company?

An increase in ROA of SK Biopharmaceuticals Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of SK Biopharmaceuticals Co impact the company?

A reduction in the ROA of SK Biopharmaceuticals Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of SK Biopharmaceuticals Co?

Some factors that can influence the ROA of SK Biopharmaceuticals Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of SK Biopharmaceuticals Co important for investors?

The ROA of SK Biopharmaceuticals Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can SK Biopharmaceuticals Co take to improve ROA?

To improve ROA, SK Biopharmaceuticals Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does SK Biopharmaceuticals Co pay?

Over the past 12 months, SK Biopharmaceuticals Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SK Biopharmaceuticals Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of SK Biopharmaceuticals Co?

The current dividend yield of SK Biopharmaceuticals Co is .

When does SK Biopharmaceuticals Co pay dividends?

SK Biopharmaceuticals Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SK Biopharmaceuticals Co?

SK Biopharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of SK Biopharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is SK Biopharmaceuticals Co located?

SK Biopharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SK Biopharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SK Biopharmaceuticals Co from 7/2/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did SK Biopharmaceuticals Co pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of SK Biopharmaceuticals Co in the year 2023?

In the year 2023, SK Biopharmaceuticals Co distributed 0 KRW as dividends.

In which currency does SK Biopharmaceuticals Co pay out the dividend?

The dividends of SK Biopharmaceuticals Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SK Biopharmaceuticals Co

Our stock analysis for SK Biopharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Biopharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.